Med-Tech

13 October 2017

MedaPhor – Parkwalk investment

By |October 13th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund has  participated in the recent financing round of Medaphor Group plc, the Cardiff University Spin-out and global provider of advanced ultrasound training simulators for medical professionals.

3 July 2017

Creavo Medical Technologies – Parkwalk closes investment

By |July 3rd, 2017|

We are pleased to announce that the Parkwalk Opportunities Fund has made an investment in Creavo Medical Technologies, a University of Leeds Spin-out company, as part of a £13.4 million fundraising.

The round was oversubscribed, exceeded Creavo’s funding target and was strongly supported by existing shareholders including IP Group plc, the University of Leeds, and new, private and […]

9 May 2017

Brainomix joins forces with Boehringer Ingelheim to help save stroke victims

By |May 9th, 2017|

Oxford – An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.

The Brainomix team has pioneered the rapid digital analysis of scans of patients admitted to hospital with stroke. […]

28 February 2017

Sphere Medical – Results for the year ended 31 December 2016

By |February 28th, 2017|

Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, announces its results for the year ended 31 December 2016.
 
Business highlights for 2016 and post year-end
 
·        Successful commercial launch of Proxima 4 in mid-December 2016 in Europe with encouraging early market reaction
·        First sales of Proxima 4 achieved
·        Over 20 […]

14 December 2016

Brainomix – International Journal of Stroke Publication

By |December 14th, 2016|

Oxford – A new clinical study was conducted by Anglia Ruskin Clinical Trials Unit reporting the performance of e-ASPECTS. In this multi-centre study, non-contrast enhanced computed tomography (NCCT) images from ischemic stroke patients were evaluated by e-ASPECTS and 3 independent neuroradiologists and compared to ground truth ASPECTS scores determined by a core imaging lab. […]

1 September 2016

Healthera – University of Cambridge Enterprise Fund III investment

By |September 1st, 2016|

We are delighted to announce that the University of Cambridge Enterprise Fund III has invested in Healthera Ltd, a provider of next-generation, pharmacy-integrated personal health management solutions, has secured seed investment from the University of Cambridge, the University of Cambridge Enterprise Fund III, FT Capital and high net worth individuals. The specific amounts are undisclosed.

This […]

31 August 2016

Brainomix – Parkwalk closes follow-on investment

By |August 31st, 2016|

We have recently closed an investment in Brainomix for the Parkwalk UK Tech Fund VII and the Opportunities Fund.

Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses for their patients.

Brainomix’s ground-breaking technology, e-ASPECTS is a clinical decision support tool that automatically implements the Alberta […]

Micrima – University of Bristol Enterprise Fund I investment

By |August 10th, 2016|

We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Micrima.

The company intends to develop and commercialise a new Breast Imaging System (MARIA) aimed at radically improving breast cancer detection and survival rates through the provision of much safer, more frequent, more comfortable and less expensive […]

21 April 2016

DefiniGEN – Parkwalk closes follow on investment

By |April 21st, 2016|

Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund IV and Parkwalk Funds

DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human cells to the drug discovery sector for use in lead optimisation and toxicity programmes.

The Company’s proprietary production […]

21 December 2015

Oxford Endovascular – Parkwalk closes University of Oxford Isis Fund investment

By |December 21st, 2015|

We are delighted to announce that the University of Oxford Isis Fund II has completed an investment in Oxford Endovascular Limited, a company developing sophisticated mesh tubes to treat patients suffering from brain aneurysms. Parkwalk invested in a £2m round alongside the new Oxford Sciences Innovation plc.

The Oxford technology uses a special laser-cut metal alloy which has a […]

11 August 2015

Brainomix – receives Biomedical Catalyst funding to develop clinical decision-making software for stroke patients

By |August 11th, 2015|

Oxford, UK: Brainomix Limited, a developer of automated medical imaging software for neurological and cerebrovascular disorders, has been awarded £633,553 by the Biomedical Catalyst, a joint programme run by the Medical Research Council (MRC) and Innovate UK. The funding is for two years and will support the development and validation of clinical decision-making support […]

26 June 2015

Parkwalk closes Orthox investment

By |June 26th, 2015|

We are pleased to announce that Parkwalk VI, the Opportunities EIS Fund and the University of Oxford Isis Fund II have made an investment in Orthox,  a tissue regenerative orthopaedic implant company with technology spun out of Oxford University.

Orthox is a medical device company founded in 2008 to exploit FibroFix, a novel silk-based biomaterial platform, for the […]

1 May 2015

Parkwalk closes Sphere Medical investment

By |May 1st, 2015|

We are pleased to announce that the Parkwalk Opportunities EIS Fund has participated in a £13m financing round into the AIM-listed Sphere Medical Holdings plc. The financing round was led by Woodford’s Patient Capital Trust plc and Chris Evans’ Arthurian Life Sciences Fund.

Sphere Medical is a dynamic company specialising in the development of innovative […]

16 February 2015

Brainomix – Positive endovascular trial uses ASPECTS

By |February 16th, 2015|

A seminal paper was published in the New England Journal of Medicine describing the results of the ESCAPE trial for endovascular treatment of stroke patients. This study shows that rapid endovascular treatment leads to significantly improved functional outcomes in stroke patients, given appropriate selection criteria.

As part of the trial, patients with small infarct core […]

Mode DX – The £35 DIY test that can spot signs of bowel cancer

By |February 16th, 2015|

Mode Diagnostics have been featured in the Daily Mail:

The £35 DIY test that can spot signs of bowel cancer: Experts say discreet kit will encourage middle-aged people to self-check
DIY testing kit for bowel cancer and other disorders has gone on sale
Results displayed on a screen with an amber warning light to seek advice
Experts say […]

8 October 2014

Brainomix – wins ACES award for ICT

By |October 8th, 2014|

University of Oxford Isis Fund I and Parkwalk portfolio company Brainomix wins ACES entrepreneurship prize which rewards companies working in health and environment:

BERLIN – 7 October 2014. Spin-outs from Germany, Switzerland and the UK won the ACES awards for academic entrepreneurship in Europe. The three awards – one each for innovative companies in life […]

30 September 2014

Brainomix – University of Oxford Isis Fund I and Parkwalk investment

By |September 30th, 2014|

We have recently closed an investment in Brainomix for the University of Oxford Isis Fund I and Parkwalk Funds.

Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses for their patients. Strokes are the third highest cause of death and the primary cause of disability worldwide […]

Oxtex – University of Oxford Isis Fund I investment

By |September 10th, 2014|

We have recently made an investment in Oxtex for the University of Oxford Isis Fund I.

Oxtex has developed a surgical implant device which addresses the problem created by the lack of sufficient skin in areas requiring reconstructive surgery.

Oxtex received the OBN Bioscience award for Best Emerging MedTech in 2011 and Best New Medtech product in 2012.

Oxtex […]

DefiniGEN Joins EBiSC Consortium

By |September 8th, 2014|

DefiniGEN (an investment in the University of Cambridge Enterprise Funds I & II), a leading provider of stem cell life science products and services has joined the European Bank for induced pluripotent stem cells (EBiSC) consortium. The consortium comprises 26 partners, and has been newly-formed with support from the Innovative Medicines Initiative (IMI) and […]

16 April 2014

Microsaic Systems – Signs pre-contract Commercial Agreement

By |April 16th, 2014|

Microsaic Systems Signs Pre-Contract Commercial Agreement with Leading Global Supplier of Scientific Instrumentation in Healthcare Markets

14 April 2014: Microsaic Systems plc (AIM: MSYS), the high technology company developing next generation mass spectrometry instruments, is pleased to announce the signing of a pre-contract commercial agreement to provide its miniature mass spectrometer – the Microsaic 4000 […]